Loading…
Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients
Endothelial injury indices, such as Endothelial Activation and Stress Index (EASIX), modified EASIX (m-EASIX), and simplified EASIX (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activato...
Saved in:
Published in: | International journal of molecular sciences 2024-10, Vol.25 (20), p.11028 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c302t-7a672f58e4929729063af9d698ceda574d5d3981ca338a9ab9a8f9adf845d4cd3 |
container_end_page | |
container_issue | 20 |
container_start_page | 11028 |
container_title | International journal of molecular sciences |
container_volume | 25 |
creator | Gavriilaki, Eleni Demosthenous, Christos Evangelidis, Paschalis Bousiou, Zoi Batsis, Ioannis Vardi, Anna Mallouri, Despina Koravou, Eudoxia-Evaggelia Spyridis, Nikolaos Panteliadou, Alkistis Karavalakis, Georgios Masmanidou, Marianna Touloumenidou, Tasoula Papalexandri, Apostolia Poziopoulos, Christos Yannaki, Evangelia Sakellari, Ioanna Politou, Marianna Papassotiriou, Ioannis |
description | Endothelial injury indices, such as Endothelial Activation and Stress Index (EASIX), modified EASIX (m-EASIX), and simplified EASIX (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor-15 (GDF-15), and soluble C5b-9 (sC5b-9) have been described as markers of endothelial injury post-hematopoietic stem cell transplantation. In the current study, we examined whether suPAR, GDF-15, and sC5b-9 levels were associated with endothelial injury indices in adult CAR-T cell recipients. The levels of these markers were measured in patients before CAR-T cell infusion and in healthy individuals with immunoenzymatic methods. We studied 45 CAR-T cell recipients and 20 healthy individuals as the control group. SuPAR, GDF-15, and sC5b-9 levels were significantly higher in the patients' group compared to the healthy control group (
< 0.001, in all comparisons). SuPAR levels at baseline were associated with the m-EASIX scores calculated at the same time point (
= 0.020), while suPAR and GDF-15 concentrations were correlated with EASIX scores at day 14 post-infusion (
< 0.001 in both comparisons). Moreover, sC5b-9 levels were correlated with the s-EASIX scores at infusion (
= 0.008) and the EASIX scores at day 14 (
= 0.005). In our study, sC5b9, suPAR, and GDF-15 levels were found to reflect endothelial injury in CAR-T cell recipients. |
doi_str_mv | 10.3390/ijms252011028 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11507105</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3120646055</sourcerecordid><originalsourceid>FETCH-LOGICAL-c302t-7a672f58e4929729063af9d698ceda574d5d3981ca338a9ab9a8f9adf845d4cd3</originalsourceid><addsrcrecordid>eNpdkktrGzEUhYfS0qRpl90WQTcOdFo9RjOjVRmc2A0YGhxnPcjSHVuuLLnSjIN_bv9J5eZB0tW5cD_OORduln0k-CtjAn8zm22knGJCMK1fZaekoDTHuKxeP5tPsncxbjCmjHLxNjthouBlTfBp9ufG22FpAd0G_8s4GSFfHHaArq2MW-P8ChxqVG_2svcBzUHB7jiM4nDdzM-_oGnwd_0aXZiugwCuN7I33qGJVAnLCUej6cUkaUKl0-gxbcyXuUgu__QczWAPNqImALoxK2c6o6Tr7QE1MXqVPEGjO5NyLp32_RqskRZduc0QDkm0URCRcWjczPMFGoO1x6ZmZ1Kh-D5700kb4cODnmW3k8vF-Ec--zm9GjezXDFM-7ySZUU7XkMhqKiowCWTndClqBVoyatCc81ETZRkrJZCLoWsOyF1VxdcF0qzs-z7ve9uWG5Bq5QdpG13wWxlOLRemvblxpl1u_L7lhCOK4J5chg9OAT_e4DYt1sTVbpGOvBDbBmhBJdY0CKhn_9DN34ILt13pHBZlJgfDfN7SgUfY4DuqQ3B7fF72hffk_hPz094oh_fhf0F9_LBPA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3120646055</pqid></control><display><type>article</type><title>Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Gavriilaki, Eleni ; Demosthenous, Christos ; Evangelidis, Paschalis ; Bousiou, Zoi ; Batsis, Ioannis ; Vardi, Anna ; Mallouri, Despina ; Koravou, Eudoxia-Evaggelia ; Spyridis, Nikolaos ; Panteliadou, Alkistis ; Karavalakis, Georgios ; Masmanidou, Marianna ; Touloumenidou, Tasoula ; Papalexandri, Apostolia ; Poziopoulos, Christos ; Yannaki, Evangelia ; Sakellari, Ioanna ; Politou, Marianna ; Papassotiriou, Ioannis</creator><creatorcontrib>Gavriilaki, Eleni ; Demosthenous, Christos ; Evangelidis, Paschalis ; Bousiou, Zoi ; Batsis, Ioannis ; Vardi, Anna ; Mallouri, Despina ; Koravou, Eudoxia-Evaggelia ; Spyridis, Nikolaos ; Panteliadou, Alkistis ; Karavalakis, Georgios ; Masmanidou, Marianna ; Touloumenidou, Tasoula ; Papalexandri, Apostolia ; Poziopoulos, Christos ; Yannaki, Evangelia ; Sakellari, Ioanna ; Politou, Marianna ; Papassotiriou, Ioannis</creatorcontrib><description>Endothelial injury indices, such as Endothelial Activation and Stress Index (EASIX), modified EASIX (m-EASIX), and simplified EASIX (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor-15 (GDF-15), and soluble C5b-9 (sC5b-9) have been described as markers of endothelial injury post-hematopoietic stem cell transplantation. In the current study, we examined whether suPAR, GDF-15, and sC5b-9 levels were associated with endothelial injury indices in adult CAR-T cell recipients. The levels of these markers were measured in patients before CAR-T cell infusion and in healthy individuals with immunoenzymatic methods. We studied 45 CAR-T cell recipients and 20 healthy individuals as the control group. SuPAR, GDF-15, and sC5b-9 levels were significantly higher in the patients' group compared to the healthy control group (
< 0.001, in all comparisons). SuPAR levels at baseline were associated with the m-EASIX scores calculated at the same time point (
= 0.020), while suPAR and GDF-15 concentrations were correlated with EASIX scores at day 14 post-infusion (
< 0.001 in both comparisons). Moreover, sC5b-9 levels were correlated with the s-EASIX scores at infusion (
= 0.008) and the EASIX scores at day 14 (
= 0.005). In our study, sC5b9, suPAR, and GDF-15 levels were found to reflect endothelial injury in CAR-T cell recipients.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms252011028</identifier><identifier>PMID: 39456810</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adult ; Aged ; Biomarkers - blood ; Disease ; FDA approval ; Female ; Growth Differentiation Factor 15 - blood ; Growth Differentiation Factor 15 - metabolism ; Hematology ; Humans ; Immunotherapy ; Immunotherapy, Adoptive - adverse effects ; Immunotherapy, Adoptive - methods ; Lymphocytes ; Lymphoma ; Male ; Middle Aged ; Mortality ; Multivariate analysis ; Pathophysiology ; Receptors, Urokinase Plasminogen Activator - blood ; Receptors, Urokinase Plasminogen Activator - metabolism ; Regression analysis</subject><ispartof>International journal of molecular sciences, 2024-10, Vol.25 (20), p.11028</ispartof><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c302t-7a672f58e4929729063af9d698ceda574d5d3981ca338a9ab9a8f9adf845d4cd3</cites><orcidid>0000-0003-0011-6997 ; 0000-0002-2008-7954 ; 0000-0003-1783-5111 ; 0000-0002-8883-8208 ; 0000-0002-2126-3251</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3120646055/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3120646055?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39456810$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gavriilaki, Eleni</creatorcontrib><creatorcontrib>Demosthenous, Christos</creatorcontrib><creatorcontrib>Evangelidis, Paschalis</creatorcontrib><creatorcontrib>Bousiou, Zoi</creatorcontrib><creatorcontrib>Batsis, Ioannis</creatorcontrib><creatorcontrib>Vardi, Anna</creatorcontrib><creatorcontrib>Mallouri, Despina</creatorcontrib><creatorcontrib>Koravou, Eudoxia-Evaggelia</creatorcontrib><creatorcontrib>Spyridis, Nikolaos</creatorcontrib><creatorcontrib>Panteliadou, Alkistis</creatorcontrib><creatorcontrib>Karavalakis, Georgios</creatorcontrib><creatorcontrib>Masmanidou, Marianna</creatorcontrib><creatorcontrib>Touloumenidou, Tasoula</creatorcontrib><creatorcontrib>Papalexandri, Apostolia</creatorcontrib><creatorcontrib>Poziopoulos, Christos</creatorcontrib><creatorcontrib>Yannaki, Evangelia</creatorcontrib><creatorcontrib>Sakellari, Ioanna</creatorcontrib><creatorcontrib>Politou, Marianna</creatorcontrib><creatorcontrib>Papassotiriou, Ioannis</creatorcontrib><title>Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Endothelial injury indices, such as Endothelial Activation and Stress Index (EASIX), modified EASIX (m-EASIX), and simplified EASIX (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor-15 (GDF-15), and soluble C5b-9 (sC5b-9) have been described as markers of endothelial injury post-hematopoietic stem cell transplantation. In the current study, we examined whether suPAR, GDF-15, and sC5b-9 levels were associated with endothelial injury indices in adult CAR-T cell recipients. The levels of these markers were measured in patients before CAR-T cell infusion and in healthy individuals with immunoenzymatic methods. We studied 45 CAR-T cell recipients and 20 healthy individuals as the control group. SuPAR, GDF-15, and sC5b-9 levels were significantly higher in the patients' group compared to the healthy control group (
< 0.001, in all comparisons). SuPAR levels at baseline were associated with the m-EASIX scores calculated at the same time point (
= 0.020), while suPAR and GDF-15 concentrations were correlated with EASIX scores at day 14 post-infusion (
< 0.001 in both comparisons). Moreover, sC5b-9 levels were correlated with the s-EASIX scores at infusion (
= 0.008) and the EASIX scores at day 14 (
= 0.005). In our study, sC5b9, suPAR, and GDF-15 levels were found to reflect endothelial injury in CAR-T cell recipients.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers - blood</subject><subject>Disease</subject><subject>FDA approval</subject><subject>Female</subject><subject>Growth Differentiation Factor 15 - blood</subject><subject>Growth Differentiation Factor 15 - metabolism</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy, Adoptive - adverse effects</subject><subject>Immunotherapy, Adoptive - methods</subject><subject>Lymphocytes</subject><subject>Lymphoma</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Pathophysiology</subject><subject>Receptors, Urokinase Plasminogen Activator - blood</subject><subject>Receptors, Urokinase Plasminogen Activator - metabolism</subject><subject>Regression analysis</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNpdkktrGzEUhYfS0qRpl90WQTcOdFo9RjOjVRmc2A0YGhxnPcjSHVuuLLnSjIN_bv9J5eZB0tW5cD_OORduln0k-CtjAn8zm22knGJCMK1fZaekoDTHuKxeP5tPsncxbjCmjHLxNjthouBlTfBp9ufG22FpAd0G_8s4GSFfHHaArq2MW-P8ChxqVG_2svcBzUHB7jiM4nDdzM-_oGnwd_0aXZiugwCuN7I33qGJVAnLCUej6cUkaUKl0-gxbcyXuUgu__QczWAPNqImALoxK2c6o6Tr7QE1MXqVPEGjO5NyLp32_RqskRZduc0QDkm0URCRcWjczPMFGoO1x6ZmZ1Kh-D5700kb4cODnmW3k8vF-Ec--zm9GjezXDFM-7ySZUU7XkMhqKiowCWTndClqBVoyatCc81ETZRkrJZCLoWsOyF1VxdcF0qzs-z7ve9uWG5Bq5QdpG13wWxlOLRemvblxpl1u_L7lhCOK4J5chg9OAT_e4DYt1sTVbpGOvBDbBmhBJdY0CKhn_9DN34ILt13pHBZlJgfDfN7SgUfY4DuqQ3B7fF72hffk_hPz094oh_fhf0F9_LBPA</recordid><startdate>20241014</startdate><enddate>20241014</enddate><creator>Gavriilaki, Eleni</creator><creator>Demosthenous, Christos</creator><creator>Evangelidis, Paschalis</creator><creator>Bousiou, Zoi</creator><creator>Batsis, Ioannis</creator><creator>Vardi, Anna</creator><creator>Mallouri, Despina</creator><creator>Koravou, Eudoxia-Evaggelia</creator><creator>Spyridis, Nikolaos</creator><creator>Panteliadou, Alkistis</creator><creator>Karavalakis, Georgios</creator><creator>Masmanidou, Marianna</creator><creator>Touloumenidou, Tasoula</creator><creator>Papalexandri, Apostolia</creator><creator>Poziopoulos, Christos</creator><creator>Yannaki, Evangelia</creator><creator>Sakellari, Ioanna</creator><creator>Politou, Marianna</creator><creator>Papassotiriou, Ioannis</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0011-6997</orcidid><orcidid>https://orcid.org/0000-0002-2008-7954</orcidid><orcidid>https://orcid.org/0000-0003-1783-5111</orcidid><orcidid>https://orcid.org/0000-0002-8883-8208</orcidid><orcidid>https://orcid.org/0000-0002-2126-3251</orcidid></search><sort><creationdate>20241014</creationdate><title>Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients</title><author>Gavriilaki, Eleni ; Demosthenous, Christos ; Evangelidis, Paschalis ; Bousiou, Zoi ; Batsis, Ioannis ; Vardi, Anna ; Mallouri, Despina ; Koravou, Eudoxia-Evaggelia ; Spyridis, Nikolaos ; Panteliadou, Alkistis ; Karavalakis, Georgios ; Masmanidou, Marianna ; Touloumenidou, Tasoula ; Papalexandri, Apostolia ; Poziopoulos, Christos ; Yannaki, Evangelia ; Sakellari, Ioanna ; Politou, Marianna ; Papassotiriou, Ioannis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c302t-7a672f58e4929729063af9d698ceda574d5d3981ca338a9ab9a8f9adf845d4cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers - blood</topic><topic>Disease</topic><topic>FDA approval</topic><topic>Female</topic><topic>Growth Differentiation Factor 15 - blood</topic><topic>Growth Differentiation Factor 15 - metabolism</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy, Adoptive - adverse effects</topic><topic>Immunotherapy, Adoptive - methods</topic><topic>Lymphocytes</topic><topic>Lymphoma</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Pathophysiology</topic><topic>Receptors, Urokinase Plasminogen Activator - blood</topic><topic>Receptors, Urokinase Plasminogen Activator - metabolism</topic><topic>Regression analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gavriilaki, Eleni</creatorcontrib><creatorcontrib>Demosthenous, Christos</creatorcontrib><creatorcontrib>Evangelidis, Paschalis</creatorcontrib><creatorcontrib>Bousiou, Zoi</creatorcontrib><creatorcontrib>Batsis, Ioannis</creatorcontrib><creatorcontrib>Vardi, Anna</creatorcontrib><creatorcontrib>Mallouri, Despina</creatorcontrib><creatorcontrib>Koravou, Eudoxia-Evaggelia</creatorcontrib><creatorcontrib>Spyridis, Nikolaos</creatorcontrib><creatorcontrib>Panteliadou, Alkistis</creatorcontrib><creatorcontrib>Karavalakis, Georgios</creatorcontrib><creatorcontrib>Masmanidou, Marianna</creatorcontrib><creatorcontrib>Touloumenidou, Tasoula</creatorcontrib><creatorcontrib>Papalexandri, Apostolia</creatorcontrib><creatorcontrib>Poziopoulos, Christos</creatorcontrib><creatorcontrib>Yannaki, Evangelia</creatorcontrib><creatorcontrib>Sakellari, Ioanna</creatorcontrib><creatorcontrib>Politou, Marianna</creatorcontrib><creatorcontrib>Papassotiriou, Ioannis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gavriilaki, Eleni</au><au>Demosthenous, Christos</au><au>Evangelidis, Paschalis</au><au>Bousiou, Zoi</au><au>Batsis, Ioannis</au><au>Vardi, Anna</au><au>Mallouri, Despina</au><au>Koravou, Eudoxia-Evaggelia</au><au>Spyridis, Nikolaos</au><au>Panteliadou, Alkistis</au><au>Karavalakis, Georgios</au><au>Masmanidou, Marianna</au><au>Touloumenidou, Tasoula</au><au>Papalexandri, Apostolia</au><au>Poziopoulos, Christos</au><au>Yannaki, Evangelia</au><au>Sakellari, Ioanna</au><au>Politou, Marianna</au><au>Papassotiriou, Ioannis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2024-10-14</date><risdate>2024</risdate><volume>25</volume><issue>20</issue><spage>11028</spage><pages>11028-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Endothelial injury indices, such as Endothelial Activation and Stress Index (EASIX), modified EASIX (m-EASIX), and simplified EASIX (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor-15 (GDF-15), and soluble C5b-9 (sC5b-9) have been described as markers of endothelial injury post-hematopoietic stem cell transplantation. In the current study, we examined whether suPAR, GDF-15, and sC5b-9 levels were associated with endothelial injury indices in adult CAR-T cell recipients. The levels of these markers were measured in patients before CAR-T cell infusion and in healthy individuals with immunoenzymatic methods. We studied 45 CAR-T cell recipients and 20 healthy individuals as the control group. SuPAR, GDF-15, and sC5b-9 levels were significantly higher in the patients' group compared to the healthy control group (
< 0.001, in all comparisons). SuPAR levels at baseline were associated with the m-EASIX scores calculated at the same time point (
= 0.020), while suPAR and GDF-15 concentrations were correlated with EASIX scores at day 14 post-infusion (
< 0.001 in both comparisons). Moreover, sC5b-9 levels were correlated with the s-EASIX scores at infusion (
= 0.008) and the EASIX scores at day 14 (
= 0.005). In our study, sC5b9, suPAR, and GDF-15 levels were found to reflect endothelial injury in CAR-T cell recipients.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39456810</pmid><doi>10.3390/ijms252011028</doi><orcidid>https://orcid.org/0000-0003-0011-6997</orcidid><orcidid>https://orcid.org/0000-0002-2008-7954</orcidid><orcidid>https://orcid.org/0000-0003-1783-5111</orcidid><orcidid>https://orcid.org/0000-0002-8883-8208</orcidid><orcidid>https://orcid.org/0000-0002-2126-3251</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1422-0067 |
ispartof | International journal of molecular sciences, 2024-10, Vol.25 (20), p.11028 |
issn | 1422-0067 1661-6596 1422-0067 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11507105 |
source | Publicly Available Content Database; PubMed Central; Coronavirus Research Database |
subjects | Adult Aged Biomarkers - blood Disease FDA approval Female Growth Differentiation Factor 15 - blood Growth Differentiation Factor 15 - metabolism Hematology Humans Immunotherapy Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Lymphocytes Lymphoma Male Middle Aged Mortality Multivariate analysis Pathophysiology Receptors, Urokinase Plasminogen Activator - blood Receptors, Urokinase Plasminogen Activator - metabolism Regression analysis |
title | Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A40%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Soluble%20Urokinase-Type%20Plasminogen%20Activator%20Receptor%20(suPAR),%20Growth%20Differentiation%20Factor-15%20(GDF-15),%20and%20Soluble%20C5b-9%20(sC5b-9)%20Levels%20Are%20Significantly%20Associated%20with%20Endothelial%20Injury%20Indices%20in%20CAR-T%20Cell%20Recipients&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Gavriilaki,%20Eleni&rft.date=2024-10-14&rft.volume=25&rft.issue=20&rft.spage=11028&rft.pages=11028-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms252011028&rft_dat=%3Cproquest_pubme%3E3120646055%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c302t-7a672f58e4929729063af9d698ceda574d5d3981ca338a9ab9a8f9adf845d4cd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3120646055&rft_id=info:pmid/39456810&rfr_iscdi=true |